Compound · clinical trials

JS111 clinical trials

Also listed in trial records as JS212 ＋JS111, AP-L1898

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 3 trials in our China register that name JS111 as an intervention. Synced 10 Nov 2026

3Current trials

1Recruiting now

3Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

JS111 is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Junshi Bioscience Co., Ltd (1). The most-studied condition is Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations.

Patient leaflets for JS111

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting133%
Not yet open133%
Active, closed133%

Trials by phase

Phase 2133%
Phase 1/2133%
Not applicable133%

Clinical trials of JS111

3 trials

Study	Phase	Status	Lead sponsor	Registers
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study NCT07518160 · ClinicalTrials.gov ↗ · Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC NCT07714304 · ClinicalTrials.gov ↗ · NSCLC Harboring EGFR Mutations	Not applicable	Not yet open	Huan Zhou	China
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations NCT06940401 · ClinicalTrials.gov ↗ · NSCLC	Phase 1/2	Active, closed	Suzhou Junjing BioSciences Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with JS111

3 conditions

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations1NSCLC1NSCLC Harboring EGFR Mutations1

By country register

Register	Trials	Recruiting
Clinical trials in China	3	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about JS111 trials

How many clinical trials are testing JS111?

3 current trials in our China register name JS111 (also registered as JS212 ＋JS111) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are JS111 trials recruiting patients?

Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors JS111 clinical trials?

Shanghai Junshi Bioscience Co., Ltd (1), Suzhou Junjing BioSciences Co., Ltd (1) and Huan Zhou (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JS111 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JS111 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JS111 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.